Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors

Transplantation Proceedings

Volumn 37, Issue 4 SUPPL., 2005, Pages 1-3

  Keogh, A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ACUTE GRAFT REJECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDITORIAL; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 16244363052     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.02.117     Document Type: Article

References (22)

1. F.C. Tsai, D. Marelli, J. Bresson Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs Am J Transplant 2 2002 539
2. D.F. Del Rizzo, A.H. Menkis, P.W. Pflugfelder The role of donor age and ischemic time on survival following orthotopic heart transplantation J Heart Lung Transplant 18 1999 310
3. J. Kobashigawa What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 1 2000 166
4. S.P. Pinney, D. Mancini Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment Curr Opin Cardiol 19 2004 170
5. Avery RK Cardiac-allograft vasculopathy 2003 N Engl J Med 349:9
6. H. Valantine, P. Rickenbacker, M. Kemna Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study Circulation 103 2001 2144
7. J. Kobashigawa, L. Miller, D. Renlund A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507
8. Kobashigawa J, Tobis J, Mentzer R,, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Transplantation In press, 2005
9. R.Y. Calne, D.S. Collier, S. Lim Rapamycin for immunosuppression in organ allografting Lancet 2 1989 227
10. F.J. Dumont, Q. Su Mechanism of action of the immunosuppressant rapamycin Life Sci 58 1996 373
11. W. Cao, P. Mohacsi, R. Shorthouse, R. Pratt, E. Morris Effects of rapamycin on growth-factor stimulated vascular smooth muscle cell DNA synthesis Transplantation 59 1995 390
12. S.O. Marx, T. Jayaraman, L.O. Go, A.R. Marks Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells Circ Res 76 1995 412
13. T. Gonwa, R. Mendez, H.C. Yang Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months Transplantation 75 2003 1213
14. Lorber M, Mulgaonkar S, Butt K,, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation In press, 2005
15. Baboolal K A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75 2003 1404
16. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626
17. H.J. Schuurman, S. Cottens, S. Fuchs SDZ RAD, a new rapamycin derivative: synergism with cyclosporine Transplantation 64 1997 32
18. S.M. Stepkowski, L. Tian, K.L. Napoli Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney allograft rejection Clin Exp Immunol 108 1997 63
19. D. Mancini, S. Pinney, D. Burkhoff Use of rapamycin slows progression of cardiac transplantation vasculopathy Circulation 108 2003 48
20. A. Keogh, M. Richardson, P. Ruygrok Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years A randomized clinical trial Circulation 110 2004 2694
21. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients N Engl J Med 349 2003 847
22. D. Mancini, M. Vigano, L.A., et al Pulpon: 24-month results of a multicenter study of Certican for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients Am J Transplant 3 suppl 5 2003 550